Limits...
Effects of bradykinin on venous capacitance in health and treated chronic heart failure.

Gunaruwan P, Maher A, Williams L, Sharman J, Schmitt M, Campbell R, Frenneaux M - Clin. Sci. (2009)

Bottom Line: Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum 12.3+/-2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3+/-3.3%, P<0.05 compared with baseline; P=not significant for difference between groups), but the increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8+/-7.8%, P<0.001 compared with baseline; P<0.05 for the difference between groups).In contrast, while the increase in blood flow in healthy volunteers (maximum 362+/-9%, P<0.001) and in ACEI-treated CHF patients (maximum 376+/-12%, P<0.001) was similar (P=not significant for the difference between groups), the increase in ARB-treated CHF patients was less (maximum 335+/-7%, P<0.001; P<0.05 for the difference between groups).Infusion of each receptor antagonist alone similarly reduced basal unstressed volume and blood flow in ACEI-treated CHF patients, but not in healthy volunteers or ARB-treated CHF patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular Medicine, Medical School, University of Birmingham, Edgbaston, UK. gunaruwan@doctors.org.uk

ABSTRACT
In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin on unstressed forearm vascular volume (a measure of venous tone) and blood flow in healthy volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-converting enzyme) inhibitors] (n=16) and ARBs (angiotensin receptor blockers) (n=14). We used radionuclide plethysmography to examine the effects of bradykinin and of the bradykinin antagonists B9340 [B1 (type 1)/B2 (type 2) receptor antagonist] and HOE140 (B2 antagonist). Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum 12.3+/-2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3+/-3.3%, P<0.05 compared with baseline; P=not significant for difference between groups), but the increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8+/-7.8%, P<0.001 compared with baseline; P<0.05 for the difference between groups). In contrast, while the increase in blood flow in healthy volunteers (maximum 362+/-9%, P<0.001) and in ACEI-treated CHF patients (maximum 376+/-12%, P<0.001) was similar (P=not significant for the difference between groups), the increase in ARB-treated CHF patients was less (maximum 335+/-7%, P<0.001; P<0.05 for the difference between groups). Infusion of each receptor antagonist alone similarly reduced basal unstressed volume and blood flow in ACEI-treated CHF patients, but not in healthy volunteers or ARB-treated CHF patients. In conclusion, bradykinin does not contribute to basal venous tone in health, but in ACEI-treated chronic heart failure it does. In ARB-treated heart failure, venous responses to bradykinin are preserved but arterial responses are reduced compared with healthy controls. Bradykinin-mediated vascular responses in both health and heart failure are mediated by the B2, rather than the B1, receptor.

Show MeSH

Related in: MedlinePlus

Absolute changes in the FBF ratio between the infused and control arms in response to bradykininBK 30, FBF during the infusion of bradykinin at 30 pmol/min; BK 300, FBF during the infusion of bradykinin at 300 pmol/min. *P<0.05 (measured by using two-way ANOVA).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC2636358&req=5

Figure 1: Absolute changes in the FBF ratio between the infused and control arms in response to bradykininBK 30, FBF during the infusion of bradykinin at 30 pmol/min; BK 300, FBF during the infusion of bradykinin at 300 pmol/min. *P<0.05 (measured by using two-way ANOVA).

Mentions: FBF increased significantly in the infused compared with non-infused arms in healthy volunteers and in both CHF patient groups (ACEI-treated and ARB-treated) (see Table 2). The increase in FBF in healthy volunteers and ACEI-treated CHF patients was similar, but both were significantly higher (P<0.05, measured by using two-way ANOVA) than in ARB-treated CHF patients (Figure 1).


Effects of bradykinin on venous capacitance in health and treated chronic heart failure.

Gunaruwan P, Maher A, Williams L, Sharman J, Schmitt M, Campbell R, Frenneaux M - Clin. Sci. (2009)

Absolute changes in the FBF ratio between the infused and control arms in response to bradykininBK 30, FBF during the infusion of bradykinin at 30 pmol/min; BK 300, FBF during the infusion of bradykinin at 300 pmol/min. *P<0.05 (measured by using two-way ANOVA).
© Copyright Policy - open-access
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC2636358&req=5

Figure 1: Absolute changes in the FBF ratio between the infused and control arms in response to bradykininBK 30, FBF during the infusion of bradykinin at 30 pmol/min; BK 300, FBF during the infusion of bradykinin at 300 pmol/min. *P<0.05 (measured by using two-way ANOVA).
Mentions: FBF increased significantly in the infused compared with non-infused arms in healthy volunteers and in both CHF patient groups (ACEI-treated and ARB-treated) (see Table 2). The increase in FBF in healthy volunteers and ACEI-treated CHF patients was similar, but both were significantly higher (P<0.05, measured by using two-way ANOVA) than in ARB-treated CHF patients (Figure 1).

Bottom Line: Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum 12.3+/-2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3+/-3.3%, P<0.05 compared with baseline; P=not significant for difference between groups), but the increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8+/-7.8%, P<0.001 compared with baseline; P<0.05 for the difference between groups).In contrast, while the increase in blood flow in healthy volunteers (maximum 362+/-9%, P<0.001) and in ACEI-treated CHF patients (maximum 376+/-12%, P<0.001) was similar (P=not significant for the difference between groups), the increase in ARB-treated CHF patients was less (maximum 335+/-7%, P<0.001; P<0.05 for the difference between groups).Infusion of each receptor antagonist alone similarly reduced basal unstressed volume and blood flow in ACEI-treated CHF patients, but not in healthy volunteers or ARB-treated CHF patients.

View Article: PubMed Central - PubMed

Affiliation: Department of Cardiovascular Medicine, Medical School, University of Birmingham, Edgbaston, UK. gunaruwan@doctors.org.uk

ABSTRACT
In the present study, we investigated the effects of basal and intra-arterial infusion of bradykinin on unstressed forearm vascular volume (a measure of venous tone) and blood flow in healthy volunteers (n=20) and in chronic heart failure patients treated with ACEIs [ACE (angiotensin-converting enzyme) inhibitors] (n=16) and ARBs (angiotensin receptor blockers) (n=14). We used radionuclide plethysmography to examine the effects of bradykinin and of the bradykinin antagonists B9340 [B1 (type 1)/B2 (type 2) receptor antagonist] and HOE140 (B2 antagonist). Bradykinin infusion increased unstressed forearm vascular volume in a similar dose-dependent manner in healthy volunteers and ARB-treated CHF patients (healthy volunteers maximum 12.3+/-2.1%, P<0.001 compared with baseline; ARB-treated CHF patients maximum 9.3+/-3.3%, P<0.05 compared with baseline; P=not significant for difference between groups), but the increase in unstressed volume in ACEI-treated CHF patients was higher (maximum 28.8+/-7.8%, P<0.001 compared with baseline; P<0.05 for the difference between groups). In contrast, while the increase in blood flow in healthy volunteers (maximum 362+/-9%, P<0.001) and in ACEI-treated CHF patients (maximum 376+/-12%, P<0.001) was similar (P=not significant for the difference between groups), the increase in ARB-treated CHF patients was less (maximum 335+/-7%, P<0.001; P<0.05 for the difference between groups). Infusion of each receptor antagonist alone similarly reduced basal unstressed volume and blood flow in ACEI-treated CHF patients, but not in healthy volunteers or ARB-treated CHF patients. In conclusion, bradykinin does not contribute to basal venous tone in health, but in ACEI-treated chronic heart failure it does. In ARB-treated heart failure, venous responses to bradykinin are preserved but arterial responses are reduced compared with healthy controls. Bradykinin-mediated vascular responses in both health and heart failure are mediated by the B2, rather than the B1, receptor.

Show MeSH
Related in: MedlinePlus